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Dengue in Hawaii 
Dengue fever, which had not been found in the state of Hawaii in 50 years, was reported on ProMED-mail. The most recent data, 
according to the Hawaii Department of Health, http:/lwww. hawaii.gov/doh/dengue/update-report.html, is that there have now 
been a total of 98 confirmed dengue cases in the state from 10 June 2001 to 8 January 2002. This includes 72 confirmed cases on 
the island of Maui, 22 on Oahu, and 4 on Kauai There have been no confirmed cases on the island of Hawaii. The most recent 
confirmed case had the onset of illness in mid-December. Public health officials have worked to educate people about dengue 
and mosquitoes, and to eliminate sources of standing water. 
West Nile virus in the Western Hemisphere 
The year 2001 witnessed a dramatic increase in the geographic range of the West Nile virus from Maine and parts of Canada in 
the north to Florida in the south and as far west as the states of Iowa, Missouri, and Louisiana. In the United States, there were 
a total of 50 human cases (five fatal). Surveillance in the United States demonstrated infection in 6403 wild birds: 6403,556 horses, 
178 sentinel chickens, and 791 mosquito pools. Although no human infections were documented outside the United States, for 
the first time the virus was confirmed in Canada (in 122 dead birds) and in the Cayman Islands (one human case). The presence 
of the virus in the Cayman Islands is of particular concern, as this may be indicative of wide spread into the neotropical avifauna 
with both the potential for further southern spread into South America and the possibility that any infected returning migratory 
birds will be widely scattered throughout North America. 
Anthrax in the United States 
As of 5 December 2001, a total of 22 cases of anthrax have been identified in the United States. A total of 11 were confirmed as 
inhalational anthrax, and 11 (seven confirmed and four suspected) were cutaneous anthrax. Direct exposure to a B. anthrucis- 
containing envelope was likely in the first nine cases and no direct exposure to envelopes containing B. anthracis powder has been 
identified for the fatal inhalational cases of anthrax in a 94 year-old woman in Connecticut and a woman in New York City. One 
possibility is that these two cases were as a result of cross-contaminated envelopes. 
The use of antimicrobial prophylaxis (ciprofloxacin or doxycycline) to prevent inhalational anthrax in individuals who were 
exposed to B. anthracis has resulted in a significant rate of adverse events. The recommended duration of antibiotic prophylaxis, 
60 days, may not always be completed.The MMWR 50(47);1051-4 (November 30,200l) noted that of the 3,428 postal employees 
receiving ciprofloxacin (the most commonly used antibiotic),who completed their survey, 666 (19%) reported severe nausea, 
vomiting, diarrhea, or abdominal pain; 484 (14%) reported fainting, light-headedness, or dizziness; 250 (7%) reported heartburn 
or acid reflux; and 216 (6%) reported rashes, hives, or itchy skin. Of those persons taking ciprofloxacin, 2X7 (8%) discontinued 
the medication; 116 (3%) discontinued the medication because of adverse events, 27 (1%) d’ iscontinued because of fear of possible 
adverse events, and 28 (1%) stopped taking the drug because they “did not think it was needed.” 
Trypanosomiasis in returning travellers 
Trypanosomiasis, spread by the tsetse fly, is re-emerging in the human population in Central and East Africa. Outbreaks were 
reported on ProMED-mail from Tanzania, Uganda, Democratic Republic of Congo, and Rwanda. This devastating disease also 
continues to destroy livestock elsewhere on the continent. Increased vigilance amongst travellers is required, as almost a dozen 
cases of trypanosomiasis have been reported in those returning to Europe and the USA from these areas of Africa. Most patients 
had been on safari in the Serengeti National Park in Tanzania and neighbouring areas. On the ground, interventions must focus 
on intensive vector control, including mass clearing of bush to reduce man-tsetse contact, aerial spraying, and provision of tsetse 
fly traps; and early diagnosis and treatment of cases. However, efforts are hampered by poor infrastructure, lack of healthcare 
resources, and emerging resistance to Melarsoprol. For the traveller, avoidance of high risk areas will reduce exposure to tsetse 
flies. Trypanosomiasis should be an important differential in the febrile patient returning from these areas of Africa. 
Ebola haemorrhagic fever 
December 2001 saw reports of an outbreak of Ebola haemorrhagic fever in Gabon, focussed around the Ogooue-Ivindo Province 
in the north-east, and in the neighbouring Republic of Congo. There have been three Ebola outbreaks in Gabon since 1994, all 
of which have occurred in the central and northeastern areas of the country. By 17th January 2002,39 cases had been confirmed 
(24 in Gabon and 15 in the Republic of the Congo), and the death toll had reached 30. <http://www.who.int/disease-outbreak- 
news/n2002/january/l6ajanuary2002.html>. In addition, there have been 9 suspected cases under investigation, and almost 200 
contacts under active follow up. The World Health Organization and its partners are working with the Gabonese authorities to 
contain the disease and to prevent spread within local communities. 
